Hyderabad-based Sigachi Industries has announced its strategic expansion into the API (Active Pharmaceutical Ingredient) business with the successful acquisition of majority stake (80%) of a state-of-the-art API manufacturing company, Trimax Bio Sciences, located in Raichur, Karnataka.

The acquisition marks a significant milestone in Sigachi's journey as it reinforces it’s commitment to providing cutting-edge solutions to the global pharmaceutical market. With this strategic move, Sigachi is poised to solidify its position as a leading player in the healthcare industry, catering to the growing demand for high-quality APIs.

The API unit, located in Raichur, Karnataka, 180kms from Hyderabad, is equipped with cutting-edge technology and is in compliance with the stringent international quality standards of USFDA, EMEA and WHO.

Additionally, the API unit is approved by USFDA for advanced & critical intermediates. With a well-established track record of excellence in research, development, and manufacturing, the acquired API unit will synergise seamlessly with Sigachi's existing portfolio of excipients and will provide one stop solution for customer’s API & non-API needs.

Sigachi Industries Limited envisions becoming a key player in the API market by leveraging its strong R&D capabilities, cutting-edge manufacturing infrastructure, and unwavering focus on quality. With a strong expertise in excipient manufacturing for Oral Dosage Formulation built over last three decades, Sigachi's foray into API business opens up new doors for further collaboration with it’s customer operating in over 60 countries.